Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

R. Perets, J. Bar, D. W. Rasco, M. J. Ahn, K. Yoh, D. W. Kim, A. Nagrial, M. Satouchi, D. H. Lee, D. R. Spigel, D. Kotasek, M. Gutierrez, J. Niu, S. Siddiqi, X. Li, J. Cyrus, A. Chackerian, A. Chain, R. A. Altura, B. C. Cho

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences